Now Pro to the question "Should Prescription Drugs Be Advertised Directly to Consumers?"
"Responsible consumer advertising has proven value in helping patients engage in more informed conversations with their healthcare providers, leading to better health outcomes. In all of our consumer advertising, we adhere to applicable FDA regulations and guidance. We also abide by the PhRMA Guiding Principles on Direct-to-Consumer (DTC) Advertising About Prescription Medicines. We follow strict internal standards that have been developed to ensure the information we share with consumers is: (1) scientifically sound; (2) balanced; (3) easy to understand; and (4) helpful in encouraging people to consult with a health care professional."
"Practicing Ethical Sales and Marketing," www.pfizer.com, 2005
[Editor's Note: Prior to the Nov. 20, 2002 statement above, Pfizer was classified as Con based on the 1984 letter quoted below.]
"The view of the Upjohn Company [now Pfizer] is that the direct advertising of prescription pharmaceuticals to consumers... would be detrimental to the pharmaceutical industry and, more importantly, a potentially disruptive element in our medical delivery system as a whole... Our view is that there is a vast difference between education and promotion... Product specific consumer ads could increase costs."
R.T. Parfet, 1984 letter to then Energy and Commerce Committee Chairman John Dingell (D-CO), reprinted in "A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection" by Julie Donohue, available at www.facultynh.syr.edu
Organizations/VIPs/Others Individuals and organizations that do not fit into the other star categories.
"At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us."
"Corporate Overview," www.pfizer.com (accessed Mar. 18, 2014)
"Pfizer is committed to collaborating with physicians and other healthcare professionals, to developing new healthcare products, to educating healthcare professionals, patients, and consumers about our medicines and to sharing clinical experience with the use of our products. Our mission is to be the most valued company to patients, consumers, customers, colleagues, investors, business partners and the communities where we work and live. This ambitious mission reflects the broader role society expects Pfizer to take in improving the human condition and experience."
"Global Policy on Interactions with Healthcare Professionals," www.pfizer.com, Oct. 20, 2013
Not membership or subscription based
$22 billion (Pfizer net income for 2013)
Ian C. Read, Chairman of the Board and CEO
# of Offices:
Offices in 45 countries (headquarters in New York, NY)
# of Staff:
Science Foundation Ireland (SFI), public-private partnership to promote biotherapeutic therapies
Merck, collaboration on anti-cancer combination studies
Ichor Medical Systems, development of TriGrid electroporation devices for therapeutic cancer vaccine regimens
Akili Interactive Labs, study mobile video game platform to detect Alzheimer's disease
University of Texas MD Anderson Cancer Center, collaboration on immune-based approaches to cancer treatment
Kissei Pharmaceutical Co., Ltd, Japan, granted Pfizer worldwide rights to develop and commercialize KUX-1151, an investigational therapy for gout and hyperuricemia
Mylan Inc, received worldwide rights from Pfizer to develop, manufacture, and commercialize a novel long-acting muscarinic antagonist compound
Siemens, master collaboration agreement to design, develop, and commercialize diagnostic tests for Pfizer
MaRS Innovation, strategic partnership to fund research
JDRF, partnership for diabetes research
Gliknik, worldwide licensing agreement for GL-2045, a drug for autoimmune diseases and cancer
CytomX, strategic collaboration to develop and commercialize multiple Probody Drug Conjugates
AstraZeneca, agreement for OTC Nexium
BIND Therapeutics, collaboration to develop multiple Accurins
Repligen, licensing agreement for spinal muscular atrophy program